@misc{oai:repo.qst.go.jp:00072781,
 author = {Yoshii, Yukie and Tashima, Hideaki and Iwao, Yuma and Takuwa, Hiroyuki and Yoshida, Eiji and Wakizaka, Hidekatsu and Yamaya, Taiga and Yoshimoto, Mitsuyoshi and Matsumoto, Hiroki and Zhang, Ming-Rong and Sugyo, Aya and Tsuji, Atsushi and Higashi, Tatsuya and 吉井 幸恵 and 田島 英朗 and 岩男 悠真 and 田桑 弘之 and 吉田 英治 and 脇坂 秀克 and 山谷 泰賀 and 吉本 光喜 and 松本 博樹 and 張 明栄 and 須尭 綾 and 辻 厚至 and 東 達也},
 month = {Apr},
 note = {Background: Cytoreductive surgery is widely used for the treatment of peritoneal dissemination in clinical practice; however, it is difficult to detect and remove tumors that are located deeply in the peritoneal cavity and easily changing the position during an operation. We have found that a PET probe 64Cu-PCTA-anti-EGFR antibody cetuximab (64Cu-cetuximab) highly accumulates in intraperitoneal tumors by intraperitoneal administration. Also, we have developed the world's first open-type PET system, called "OpenPET", which has open space for conducting surgery while monitoring objects at high resolution in real time. In this study, we examined a feasibility of an OpenPET-guided surgery with 64Cu-cetuximab to detect and remove tumors deeply located in the peritoneal cavity. Methods: Mice bearing HCT116-RFP tumors transplanted with Matrigel at deep sites in the peritoneal cavity were used. 64Cu-cetuximab (7.4 MBq / mouse) was administered intraperitoneally and at 24 h later, the OpenPET-guided surgery was performed with a small prototype of OpenPET, having a spatial resolution of about 2 mm. All animal experiments were approved by the institutional ethics committee. Results: During OpenPET-guided surgery, tumors were clearly detected behind other organs in the peritoneal cavity. The measurement time required to accumulate sufficient data to identify tumors was approximately 10 – 30 s. Tumors (≥ 3 mm in diameter) located deep inside the peritoneal cavity could be resected by surgery with OpenPET real-time imaging. OpenPET was useful in confirming the presence or absence of residual tumors during an operation. Conclusions: We demonstrated that the OpenPET-guided surgery with 64Cu-cetuximab would be promising to detect and remove intraperitoneal tumors deeply located in the peritoneal cavity. This method could provide a novel strategy for cytoreductive surgery of peritoneal dissemination., 12th World congress of the world federation of nuclear medicine and biology},
 title = {Evaluation of a PET-guided surgery with 64Cu-labeled cetuximab to resect tumors deeply located in the mouse peritoneal cavity},
 year = {2018}
}